
ORIGINAL RESEARCH ARTICLE**Human Immunodeficiency Virus and Hepatitis B Virus Co-infection
in a Tertiary Care Hospital From Rural Area**

Milind Davane¹, Bhausaheb Munde², Jyoti Jojan³ and Basavraj Nagoba⁴

*Assistant Professor, Department of Microbiology, MIMSR Medical College, Latur¹,
Associate Professor, Department of Microbiology, Government Medical College,
Chandrapur², Former Assistant Professor, Department of Microbiology, MIMER Medical
College, Talegaon Dabhade, Pune³, Asst. Dean (R&D) and Professor, Department of
Microbiology, MIMSR Medical College, Latur, Maharashtra, India⁴.*

Abstract:**Background:**

The Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV) are devastating viruses that share certain epidemiological characteristics such as risk population and transmission routes. Because of this, HIV positive individuals are at risk of co-infection with Hepatitis B virus. The reports show that co-infection by HIV/HBV causes increased morbidity and mortality as compared to HIV and HBV mono-infection.

Objectives:

The present study was undertaken to determine the prevalence of Hepatitis B virus co-infection in HIV positive patients.

Materials and Methods:

A total of 1000 clinically suspected HIV infected cases attending the Sexually transmitted disease (STD) clinic were selected. The blood samples were collected by taking all aseptic precautions. The serum samples were screened by Comb –AIDS test for HIV and confirmed as per National Aids Control Organization (NACO) guidelines and then HIV positive patients were screened for Hepatitis B surface antigen (HBsAg) marker by immunochromatographic test (Hepacard).

Results:

Out of 1000 clinically suspected cases, 348 (34.8%) were positive for HIV. Out of 348, 186(53.44%) were male and 162(46.55%) were females. Among a total of 348 HIV patients, six cases were found positive for HBsAg. Thus, HIV/HBV co-infection was detected in 1.72% cases in this study.

Conclusion:

The results indicate that the prevalence of co-infection in our area is comparatively lower as compared to other geographical areas.

Keywords:

HIV, Hepatitis B virus, Co-infection

How to cite this article: Milind Davane, Bhausahab Munde, Jyoti Jojan and Basavraj Nagoba Human Immunodeficiency Virus and Hepatitis B virus co-infection in a Tertiary Care Hospital from Rural Area. Walawalkar International Medical Journal 2019; 6(1):1-10 <http://www.wimjournal.com>

Address for correspondence:

Dr. Basavraj Nagoba , Department of Microbiology,

MIMSR Medical College, Latur, Maharashtra, India.

Fax : +91 2382 227246, Email- dr_bsnagoba@yahoo.com

Mob-9423075786

Received date: 06/05/2019

Revised date: 09/09/2019

Accepted date: 12/09/2019

Introduction:

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), about 33 million people are infected with Human Immunodeficiency Virus (HIV) worldwide and majority of them live in Asia and Africa. India has the highest HIV/AIDS prevalence in the world with an estimated 5.7 million people living with HIV/AIDS.¹ Hepatitis B is a fatal infection of liver caused by Hepatitis B Virus (HBV). Both HIV and Hepatitis B are transmitted through sexual and percutaneous routes. Thus co-infection of HIV and Hepatitis B virus is common. Hepatitis B is reported to be 50 to 100 times more infectious than HIV.² Both HBV and HIV are noxious viruses that share certain epidemiological characteristics such as risk population and transmission routes. Because of this HIV positive individuals are at risk of co-infection with Hepatitis B virus.³⁻⁵ The seroprevalence for HIV and HBV co-infection ranges from 6.3% to as high as 39%.⁶⁻⁸ The reports show that co-infection by HIV/HBV causes increased morbidity and mortality as compared to HIV and HBV mono-infection. The interaction between HIV and HBV is an important issue which

suggests that HIV/HBV co-infection has negative impact on liver disease caused by these viruses.⁹⁻¹⁰ HIV/HBV co-infected patients are at increased risk of developing cirrhosis, having higher levels of HBV replication, having lower rates of spontaneous resolution of HBV infection and having a higher risk of activation of previous infections.^{9,11,12}

Whether HBV affects HIV progression has been a matter of much debate. However there are evidences that suggest that there is faster progression of HIV to AIDS defining illness in patients co-infected with HBV.¹³⁻¹⁴

Center for Disease Control (CDC) and prevention recommends all HIV infected patients should be screened for HBV and those susceptible should be vaccinated accordingly.¹⁵⁻¹⁷

There are very few studies done abroad as well as in India on prevalence of HBV co-infection in HIV infected patients. Therefore, the present study was undertaken to determine the prevalence of Hepatitis B virus infection in HIV positive patients at Tertiary Care Hospital in Latur District of Maharashtra, India.

Materials and Methods:

This study was conducted in Department of Microbiology, MIMSR Medical College, Latur District, Maharashtra, India from September 2010 to June 2014.

A total of 1000 clinically suspected HIV infected cases attending the Department of Skin and Venereal Diseases (VD) were selected. The blood samples were collected by taking aseptic precautions. Five ml of venous blood samples were collected from the patients. While collecting the blood samples the arm of subject was tied with tourniquet above the elbow joint to make the veins prominent. A vein was selected and cleaned with cotton swab dipped in spirit, and then a sterile 5 ml syringe with needle was used to pierce the vein and collect 5 ml of blood which was transferred aseptically in to a sterile dry plain bottle. The blood was allowed to clot for 30 minutes and centrifuged to get serum sample.

The serum samples were screened by Comb – AIDS test- a Dot immunoassay test that employs the same principle as Enzyme Immuno Assay (EIA) in which the immobilized antigen-antibody complex is visualized by means of color producing (chromogenic) reaction. The test was performed by adding and mixing two drops of sample to each of the wells. The Comb was placed and

sample was incubated at room temperature for 10 min. The comb was rocked in between during incubation. Four drops (0.2 ml) of colloidal gold signal reagent was dispensed into each of another set of unused micro-test wells. The comb was removed and blotted on absorbent material. The comb with the tip pointing down was rocked forward and backward in the wash solution for about 10 times, and then again the tips of the arm were blotted. The comb then was placed into well containing colloidal gold signal reagent by incubating at room temperature for 10 min. After incubation the Comb was washed again and observed for chromogenic reaction. Presence of pink colored spot in the “test” and “control” area was reported positive for HIV and confirmed as per the Strategy IIB of NACO guidelines and then HIV positive patients were screened for HBsAg marker by immunochromatographic test (Hepacard), which is a one step immunoassay based on the antigen capture, or “sandwich” principle. The test was performed by adding two drops of human serum/plasma specimen into the sample well and allowed to react for 20 minutes. Formation of pink line in test as well as control area was considered as positive.

Table No. 01 : Surveys of prevalence of HBV/HIV co-infections in the world

Author	Publication year	Country	Prevalence of HBV/HIV co- infections (%)
Present study	2014	India	1.72
Okworiet al. ¹⁸	2013	Nigeria	11
Ekanem et al. ¹⁹	2013	----	12.1
Muhammad hamzaet al. ²⁰	2013	Nigeria	12.3
FarhangBabamahmmodiet al. ²¹	2012	Iran	11.3
Kaur et al. ²²	2012	India	6.34
Ankuret al. ²³	2012	India	1.7
Suresh et al. ²⁴	2012	India	21
Kapembwa et al. ²⁵	2011	Zambia	9.9
Moore et al. ²⁶	2010	Malawi	6.7
Di Bisceglieet al. ²⁷	2010	South Africa	4.8
Hussain et al. ²⁸	2006	India	0.2
Okothet al. ²⁹	2006	Kenya	15
Deborah ³⁰	2005	---	8.7
Otedoet al. ³¹	2004	Kenya	47
Ejeleet al. ³²	2004	Nigeria	9.7
Rouetet al. ³³	2004	Coted'slvoire	09
Mustapha et al. ³⁴	2004	Gombe Nigeria	26.5
Kasoloet al. ³⁵	2003	Zambia	31.3
Ampofoet al. ³⁶	2002	Nigeria	15
Sudet al. ³⁷	2001	Nigeria	22.2
Treitingeret al. ³⁸	2000	Brazia	3.1
Dimitrakopolouset al. ³⁹	2000	Greek	67.4
Ramanammaet al. ⁴⁰	2000	India	14.3
Lodenyoet al. ⁴¹	2000	South Africa	06

Results:

Out of 1000 clinically suspected cases of HIV, 348 (34.8%) were positive for HIV. Out of 348, 186 (53.44%) were male and 162 (46.55%) were females. Almost all HIV positive cases were from age group 20-50 years with a negligible number of cases from the age group below 20 years and age group above 50 years. Among the total of 348 HIV positive patients, six cases (1.72%) were found positive for HBsAg. Thus, HIV/HBV co-infection was detected in 1.72% cases.

Discussion:

Though the routes of transmission are same in HIV and HBV infections, the prevalence of co-infection varies from place to place. Different prevalence rates from different geographical areas have been reported in various earlier studies.^{23,28,31,35,39} In the present study, a prevalence rate of co-infection was found to be 1.72%. Although this finding of a very low prevalence rate of HBV co-infection with HIV is consistent with studies by Ankur et al.²³ and Hussain et al.²⁸ and fairly correlates with the findings of these studies, it appears to be very low when compared with various other studies from other countries^{31,35,39} and even from other studies from India^{22,24,40} who report higher prevalence rates in their studies. The very low prevalence rate of co-infection may be attributed to the differences in the study groups and prevalence of HBsAg in the community in particular geographical area. A great variation in the pattern of HBV/HIV co-infection has been reported in different studies (Table no. 1) indicating that pattern of co-infection varies from place to place.

HIV has a substantial impact on the course and the outcome of HBV disease. The rate of HBV viral clearance is decreased in HIV infected patients after an acute HBV infection. The co-infected patients progress to liver disease more rapidly with a shortened period between acquisition of infection and end stage liver disease.^{42,43} The studies show that HBV reactivation and replication are enhanced in co-infected patients.⁴⁴

The effects of HBV infection on progression of HIV disease are less clear. The finding that some HBV products, such as HBV-x protein enhance HIV replication suggesting that HBV could have an impact in HIV progression.⁴⁵ However, these findings have not been supported by clinical studies.

Conclusion:

The findings of the present study indicate that the prevalence of co-infection in our area is comparatively lower as compared to other geographical areas suggesting that the prevalence rate of co-infection can change from country to country and even from region to region in same country.

Conflict of Interest: None to declare

Source of Funding: Nil

References:

- 1) Koop CE. Hepatitis C: An epidemic for any one, world-wide prevalence. DHMC 200. Available from <http://www.epidemic.org/the Facts/the Epidemic/worldprevalence/>.
- 2) World Health Organizations. Fact sheet No.204, July (2012).
- 3) Fainboim H, Gonzafiez J, Fassio E, Martinez A, Otegui L, Eposto M, Cahn P, and et al. Prevalence of Hepatitis Viruses in an anti-human immunodeficiency Virus-Positive population from Argentina. A Multicenter Study. *J. Viral. Hepat.*1999;6: 53-57.
- 4) Koike K, Tsukada K, Yotsuyangi H, Moriya K, Kikuchi Y, Oka S, Kimura. Prevalence of co-infection with human immunodeficiency virus and hepatitis c virus in Japan. *Hepatol. Res.*2007;37:2-5.
- 5) Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. *J. Am. Med. Ass.* 2002;288:199-206.
- 6) Uneke CJ, Ogbu O, Inyama GI, Njoku MO, IdokoJH Prevalence of hepatitis-B surface antigen among blood donars and human immunodeficiency virus-infected patients in Jos. Nigeria. *Mem. Inst. Oswalo. Cruz.* 2005;100:13-16.
- 7) Puoti M, Aiiroldi M, Bruno R Hepatitis B virus coinfection in HIV subjects. *AIDS. Rev.*2002;4:27-35.

- 8) Mendes-Correa MC, Barone AA, Cavalheirp N P, Tengan FM, Guastini C. Prevalence of hepatitis B and C in the sera of patients with HIV infection in Sao Paulo, Brazil. *Rev. Inst. Med. Trop. S Paulo.* 2000; 42: 81-85.
- 9) Feld JJ, Ocama P, Ronald A. The liver in HIV in Africa. *Antivir. Ther.* 2005; 10:953-965.
- 10) Benhamou Y, Bocher M, Di Martino V, Charlotte F, Azria F, Coutellier A, and et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C co-infected patients. *Hepatology.* 1999;30: 1054-1058.
- 11) Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, and et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. *AIDS.* 1997; 11:597-606.
- 12) Kellerman SE, Hnson DL, Menaghten AD, Fleming PL. Prevalence of chronic hepatitis B in human immunodeficiency virus-infected subjects. *J. Infect. Dis.* 2003;188: 571-577.
- 13) Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Poynard T, Rockstroth J. Care of patients with chronic hepatitis C and HIV confection: recommendations from the HIV-HCV international panel. *AIDS.* 2002;16:813-828.
- 14) Greub G. Clinical progression, survival , and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV cohort study. *Lancet.* 2000;356: 1800-1805.
- 15) Bica I, McGovern B, et al. Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection. *Clin. Infect. Dis.* 2001;32:492-497.
- 16) Tankhiwale SS, Khadse RK, Jalgaonkar SV. Sero-prevalence of anti HCV and hepatitis B surface antigen in HIV infected patients. *Indian. J. Med. Microbiol.* 2003; 21: 268-270.
- 17) GhanShyam P, Saikia N, Khanna S. HIV/HBV and HIV/HCV co-infection. *Gastroenterol. Today.* 2005; 9:178-182.
- 18) Okwori AEJ, Alabi SS, Ngwai YB, Makut MD, Obiekezie SO, Ishaleku D, and et al . *IOSR-JDMS.* 2013;9:70-75.
- 19) Ekanem US, Eyoh JE, Esubok NU. Prevalence of hepatitis B virus infection among HIV patients seen in University of UYO teaching hospital(UUTH) UYO. *Int. J. Res. Biosciences.* 2013;2:92-98.
- 20) Muhammad Hamza, AdamuAlhajisamaila, Ahmad MaifadaYakasai, Musa Babashani, Musa Muhammad Borodo, AbdulrazaqGarba Habib. *Nigerian. J. Basic. Clin. Scien.* 2013;10:76-80.

- 21) Farhang B, Muhammad Ali H G, Muhammad M N, Leila D. Med. GlasLjek. Komore. Zenicko-doboj. Kantona. 2012;9:299-303.
- 22) Kaur S, Garg M, Singh S, Mohan A, Gupta S, Kaur S. Co-infection of Hepatitis B and Hepatitis C viruses in HIV infected individuals in a rural setting in north India. J. Adv. Reas. Biol. Scien.2012;4: 62-64.
- 23) Ankur G, Sapna G, Ankit L, Arti A. Very low prevalence of Hepatitis B and C co-infection in HIV-positive medical inpatient in a tertiary care hospital in Agra(UP), Northern India.Indian. J. Sex. Transm. Dis. 2012;33:147-148.
- 24) Suresh B S, Sathyanarayan MS, Mariraj J, Krishna S. Seroprevalence of HIV-HBV co-infection.Al. Ameen. J. Med. Sci.2012;5:183-186.
- 25) Kapembwa KC, Goldman JD, Lakhi S, Banda Y, Bowa K, VermundSH,and et al. HIV, hepatitis B and hepatitis C in Zambia. J. Global. Infect. Dis.2011; 3:269-274.
- 26) Moore E, Beabesworth MB, Chaponda M, Mhango B, Faragher B, Njala J, and et al : Favourable one – year ART outcomes in adult Malawians with hepatitis B and C co-infection. J. Infect. 2010; 61:155-163.
- 27) Di Bisceglie A M, Maskew M, Schulze D, Reyneke A, Mcnmara L, Firnhaber C. HIV – HBV co-infection among South African patients receiving antiretroviral therapy. Antivir. Ther. 2010;15:499-503
- 28) Hussain T, Kulshreshtha KK, Sinha S, Yadav VS, Katoch VM. HIV, HBV, HCV, and syphilis co-infection among patients attending the STD clinics of District hospitals in Northern India. Internat. J. Infect. Dis.2006;10:358-363.
- 29) Okoth F, Mbuthia J, Gatheru Z, Murila F, Kanyingi F, Mugo F, and et al. Seroprevalence of hepatitis B markers in pregnant women in Kenya. East. Afr. Med. J. 2006;83:485-493.
- 30) Deborah K, Amanda M, S.de Wit, Francisco A, Bruno L, Christine K, and et al . Hepatitis B and HIV : Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro SIDA cohort. AIDS. 2005;19:593-601.
- 31) Otedo AE. HBV:HIV co-infection at Kisumu district hospital, Kenya. East. Afr. Med. J.2004;81:626-630.
- 32) Ejele OA, Nwauche CA, Erhabor O: The prevalence of Hepatitis B surface antigenaemia in HIV positive patients in the Niger Delta Nigeria. Niger. J. Med. 2004;13:175-179.

-
- 33) Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, and et al: HBV and HCV prevalence and viremia in HIV-positive and HIV-negative pregnant women in Abidjan,Coted'Ivoire: The ANRS 1236 study. *J. Med. Virol.*2004;74:34-40.
 - 34) Mustapha S, Jibrin Y: The prevalence of hepatitis B surface antigenaemia in patients with Human Immunodeficiency Virus(HIV) infection in Gombe Nigeria. *Ann. African. Med. J.* 2004;3:10-12.
 - 35) Kasolo F, Sakala I, Baboo K: Hepatitis B virus infection in human immunodeficiency virus seropositive patients at the University Teaching Hospital, Lusaka, Zambia: Interrelationship.(Abstract no.963)2nd IAS. Paris, France: Conference on HIV Pathogenesis and Treatment ;2003.
 - 36) Ampofo W, Nil-TrebiN,Ansah J, Abe K, Naito H,AidooS,and et al: Prevalence of bloodborne infectious diseases in blood donors in Ghana. *J. Clinical. Microbiol.* 2002;40:3523-3525.
 - 37) Sud A, Singh J, Dhiman RK, Wanchu A, Singh S, Chawia Y:Hepatitis B virus co-infection in HIV infected patients. *Trop. Gastroenterol.* 2001;22:90-92.
 - 38) Treitinger A, Spada C, Ferreira LA, and et al. Hepatitis B and Hepatitis C prevalence among blood donors and HIV-1 infected patients in Florianopolis-Brazil. *Braz. J. Infect. Dis.*2000;4:192-196.
 - 39) Dimitrakopolous A, Takou A, Haida A, and et al. The prevalence of Hepatitis B and C in HIV positive Greek patients, relationship to survival decreased AIDS patients. *J. Infect. Dis.* 2000;40:127-31.
 - 40) Ramanamma MV, Ramani TV. Incidence of Hepatitis B infection in Visakhapatnam.Indian. *J. Med. Microbiol.* 2000;18:170-171.
 - 41) Lodenyo H, Schoub B, Ally R, KairuS,Segal I:Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath, Johannesburg. *East. Afr. Med. J.*2000;77:13-15.
 - 42) Colin JF, Cazals-Hatem D, LorientMA,and et al. Influence of human immunodeficiency virus infection on chronic Hepatitis B in homosexual men. *Hepatology.*1999;29:1306-1310.
 - 43) PuotiM, SpinettiA,Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. *J. Acquir. Immune. Defic. Syndr.*2000;24:211-217.
 - 44) Brook MG, R Gilson R and Wilkins EL. BHIVA Guidelines: coinfection with HIV and Chronic hepatitis B virus. *HIV. Medicine.* 2003;4:42-51

- 45) Hsin-Yun Sun, Wang-Huei Sheng, Mao-Song Tsai, Kuan-Yeh Lee, Sui-Yuan Chang, and Chien-Ching Hung. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. *World. J. Gastroenterol.* 2014;20:14598–14614.